Advertisement

Wiener Medizinische Wochenschrift

, Volume 163, Issue 3–4, pp 102–105 | Cite as

Efficacy and safety of Echinaforce® in respiratory tract infections

  • Andreas SchapowalEmail author
main topic

Summary

Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinaforce®. A randomised, double-blind, placebo-controlled study over four months confirms that Echinaforce® supports the immune resistance and acts directly against a series of viruses. Echinaforce® is efficacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment.

Keywords

Echinaforce® Respiratory tract infections Immunomodulation and antiviral efficacy 

Wirksamkeit und Sicherheit von Echinaforce® bei Atemwegsinfekten

Zusammenfassung

Echinaforce® ist der standardisierte Extrakt von Echinacea purpurea (Bioforce, Schweiz). Jüngste Studien zeigen eine Immunmodulation und breite antivirale Effekte gegen Atemwegsviren. Hä-magglutinin und Neuraminidase werden blockiert. Im Gegensatz zu Oseltamivir bewirkt Echinaforce® keine Resistenz. Eine randomisierte, plazbokontrollierte Doppelblindstudie über vier Monate bestätigt, dass Echinaforce® die Immunabwehr unterstützt und direkt gegen häufige Atemwegsviren wirkt. Echinaforce® ist bei Atemwegsinfekten effizient und sicher in der Langzeit- und Kurzzeit-Prävention, sowie in der Akutbehandlung.

Schlüsselwörter

Echinaforce® Atemwegsinfekte Immunmodulation und antivirale Wirksamkeit 

Notes

Conflict of interest

The author declares that there is no conflict of interest.

References

  1. 1.
    Rotbart HA, Hayden FG. Picornavirus infections: a primer for the practitioner. Arch Fam Med. 2000;9(90):913–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Fendrick AM. Viral respiratory infections due to rhinoviruses: current knowledge, new developments. Am J Ther. 2003;10:193–202.PubMedCrossRefGoogle Scholar
  3. 3.
    Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey 1996. In: Vital and Health Statistics Series 10. Data from the National Health Survey; 1999. pp. 1–203.Google Scholar
  4. 4.
    Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–494.PubMedCrossRefGoogle Scholar
  5. 5.
    Johnston SL. Problems and prospects of developing effective therapy for common cold viruses. Trends Microbiol. 1997;5(2):58–63.PubMedCrossRefGoogle Scholar
  6. 6.
    Jefferson T. Mistaken Identity: seasonal influenza versus influenza-like illness. Clin Evid. 2009;10:1-4. http://www. clinicalevidence.com/x/mce/file/05-10-09.pdf.Google Scholar
  7. 7.
    Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ. 1995;310:1225–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardised Echinacea, a potent antiviral herbal extract. Antiviral Res. 2009;83:165–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Pleschka S, Stein M, Schoop R, et al. Anti-viral properties and mode of action of standardised Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virol J. 2009;6:197.PubMedCrossRefGoogle Scholar
  10. 10.
    Schapowal A. The triple action of the herbal medicine Echinaforce in the treatment of cold and flu-like infections. Swiss J Integr Med. 2011;23:1–5.CrossRefGoogle Scholar
  11. 11.
    Bonnet F, Lewden C, May T, et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis. 2005;37:482–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Ritchie MR, Gertsch J, Klein P, et al. Effects of Echinaforce® treatment on ex vivo-stimulated blood cells. Phytomed. 2011;18(10):826–31.CrossRefGoogle Scholar
  13. 13.
    Jawad M, Schoop R, Suter A, et al. Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2012. doi:10.1155/2012/841315.Google Scholar
  14. 14.
    Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. JHSB. 1983;24:385–96.Google Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  1. 1.Allergy ClinicLandquartSwitzerland

Personalised recommendations